Watchlist

Watchlist
ACADIA Pharmaceuticals Inc. (ACAD)
ACADIA Pharmaceuticals Inc. (ACAD)
ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Damien McDevitt, Ph.D., has joined ACADIA as Senior …
Positive Market In 2017 - Cramer's Mad Money (12/11/17)
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, December 11. What's the reason behind the market's endless rally? "Stocks have indeed come very far, very fast, we're right on the cusp of multiple rate hikes, there was a terrorist attack in Times …
Your Daily Pharma Scoop: Acadia Valuation, Galectin Plunges, Revance Positive Result
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea…
Can Acadia Pharmaceuticals Be A Prudent Bet For Long-Term Investors?
In the past 52-weeks, shares of Acadia Pharmaceuticals (NASDAQ: ACAD ), a bioscience firm, focusing on the development and commercialization of therapeutics to treat central nervous system disorders increased by $2.12 to trade at $30.16 for 7% profits (as of Dec. 1, 2017). Despite the modest g…
Acadia Pharmaceuticals: The Harmony Trial And Buyout Potential
Acadia Pharmaceuticals ( ACAD ) is a small pharmaceutical company which currently markets Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis and is also developing the drug in additional indications. The aim of this ar…
ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 29 th Annual Piper Jaffray Healt…
Acadia Pharmaceuticals: Risky, But Potentially Very Lucrative
ACADIA Pharmaceuticals (ACAD) is an interesting biotechnology company which has been around for a quarter of a century, yet only has one marketed product at this point. While sales of NUPLAZID are ramping up quite nicely, the current growth and indication trajectory is not enough to turn a p…
Biotech Forum Daily Digest: Behind Omeros' Blowout Results
A cynic is a man who, when he smells flowers, looks around for a coffin . H.L. Mencken The high beta parts of the market continued to take it on the shin while the large cap indices remain placid last week. The S&P 500 and Dow posted small losses on the week as both …
ACADIA Pharmaceuticals' (ACAD) CEO Steve Davis on Q3 2017 Results - Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2017 Results Conference Call November 07, 2017 05:00 AM ET Executives Lisa Barthelemy - Senior Director of IR Steve Davis - President and CEO Todd Young - EVP and CFO Michael Yang - EVP and CCO Dr. Serge Stankovic - EVP and Head, R&D …
Your Daily Pharma Scoop: Valeant Remains Risky, Novartis's Kisqali, Tesaro Tumbles
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Valeant Today we will disc…
ACADIA Pharmaceuticals Inc. (ACAD)